Analyst Ratings for Myriad Genetics (MYGN)
MYGN Rating Summary
MYGN Price Target Summary
- Highest: $8.50 (Piper Sandler)
- Lowest: $4.20 (Jefferies)
- Average: $6.34
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
=
Avg. $ Target:
$6.34 (+23.1%)
* Over Last 12-Mos
Rating Score: 2.3 / 10
Percentile Rank: 18%
Rating Score: 2.3 / 10
Percentile Rank: 18%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/21/2025 | Scotiabank | Sung Ji Nam | Downgrade | Sector Perform (Sector Outperform) |
6.00 (20.00) |
4.43 (5.15) |
16.25% | Details |
| 5/8/2025 | Wolfe Research | Doug Schenkel | Downgrade | Peerperform (Outperform) |
N/A (N/A) |
7.27 (5.15) |
-29.16% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
